rs78802634
Cystic Fibrosis related |
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(A;G) | 3 | cystic fibrosis carrier |
(C;C) | 0 | common in complete genomics |
(G;G) | 0 | common in clinvar |
Make rs78802634(A;A) |
Reference | GRCh38 38.1/141 |
Chromosome | 7 |
Position | 117611707 |
Gene | CFTR |
is a | snp |
is | mentioned by |
dbSNP | rs78802634 |
dbSNP (classic) | rs78802634 |
ClinGen | rs78802634 |
ebi | rs78802634 |
HLI | rs78802634 |
Exac | rs78802634 |
Gnomad | rs78802634 |
Varsome | rs78802634 |
LitVar | rs78802634 |
Map | rs78802634 |
PheGenI | rs78802634 |
Biobank | rs78802634 |
1000 genomes | rs78802634 |
hgdp | rs78802634 |
ensembl | rs78802634 |
geneview | rs78802634 |
scholar | rs78802634 |
rs78802634 | |
pharmgkb | rs78802634 |
gwascentral | rs78802634 |
openSNP | rs78802634 |
23andMe | rs78802634 |
SNPshot | rs78802634 |
SNPdbe | rs78802634 |
MSV3d | rs78802634 |
GWAS Ctlg | rs78802634 |
Max Magnitude | 3 |
Cystic fibrosis; c.3266G>A, p.Trp1089Ter
named i5011848 by 23andMe
FTDNA & MyHeritage name: VG07S29406
ClinVar | |
---|---|
Risk | rs78802634(A;A) |
Alt | rs78802634(A;A) |
Reference | Rs78802634(G;G) |
Significance | Pathogenic |
Disease | Cystic fibrosis |
Variation | info |
Gene | CFTR |
CLNDBN | Cystic fibrosis |
Reversed | 0 |
HGVS | NC_000007.13:g.117251761G>A |
CLNSRC | OMIM Allelic Variant |
CLNACC | RCV000007615.7, |
[PMID 153719] Electromagnetic measurements of metacarpal and digital blood flow in the pony.
[PMID 1284534] Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium.
[PMID 10794365] Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations.
[PMID 10923036] Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France.
[PMID 11336401] Prevalence of cystic fibrosis mutations in Israeli Jews.
[PMID 15948195] Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening.